Literature DB >> 16393681

Immunohistochemical staining for claudin-1 can help distinguish meningiomas from histologic mimics.

Hejin P Hahn1, Elizabeth A Bundock, Jason L Hornick.   

Abstract

The histologic distinction between meningiomas and other tumors of the central nervous system occasionally can be difficult. Claudin-1 is a tight junction-associated protein recently shown to be expressed in anaplastic meningiomas. The purpose of this study was to determine whether immunohistochemical staining for claudin-1 could help distinguish meningiomas from histologic mimics, compared with commonly used markers. Tissue sections from 10 meningothelial meningiomas, 20 fibrous meningiomas, 10 atypical meningiomas, 7 solitary fibrous tumors of the meninges, 5 meningeal hemangiopericytomas, and 7 vestibular schwannomas were stained immunohistochemically for claudin-1, epithelial membrane antigen, S-100 protein, CD34, and glial fibrillary acidic protein. In total, 21 (53%) of 40 meningiomas were immunoreactive for claudin-1, whereas none of the other tumors were positive. In contrast, there was considerable overlap in the distribution of the other antibodies evaluated. Claudin-1 seems to be a specific marker for meningiomas in this context. Although its sensitivity is relatively low, claudin-1 may be helpful in a panel of immunostains to distinguish meningiomas from histologic mimics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16393681     DOI: 10.1309/G659-FVVB-MG7U-4RPQ

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  14 in total

1.  Expression of p40 (∆Np63) protein in meningiomas, an unexpected finding: immunohistochemical study and evaluation of its possible prognostic role.

Authors:  Elia Guadagno; Marialaura Del Basso De Caro; Sara Pignatiello; Concetta Sciammarella; Domenico Solari; Paolo Cappabianca; Francesco Maiuri; Flavia Dones
Journal:  J Neurooncol       Date:  2016-07-09       Impact factor: 4.130

Review 2.  Ear and Temporal Bone Pathology: Neural, Sclerosing and Myofibroblastic Lesions.

Authors:  A N Flaman; J K Wasserman; D H Gravel; B M Purgina
Journal:  Head Neck Pathol       Date:  2018-08-01

Review 3.  Role of Immunohistochemistry in the Diagnosis of Solitary Fibrous Tumor, a Review.

Authors:  Bita Geramizadeh; Mahsa Marzban; Andrew Churg
Journal:  Iran J Pathol       Date:  2016

4.  Wilms tumor-1, claudin-1 and ezrin are useful immunohistochemical markers that help to distinguish schwannoma from fibroblastic meningioma.

Authors:  Avninder Singh; Ashwani Kumar Mishra; Kris Ylaya; Stephen M Hewitt; Karam Chand Sharma; Sunita Saxena
Journal:  Pathol Oncol Res       Date:  2011-09-10       Impact factor: 3.201

5.  Immunohistochemical and genetic markers to distinguish hemangiopericytoma and meningioma.

Authors:  Penglai Zhao; Tongming Zhu; Qisheng Tang; Hongyi Liu; Jianhong Zhu; Wenbin Zhang
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 6.  Intraoral perineurioma, soft tissue type: report of five cases, including 3 intraosseous examples, and review of the literature.

Authors:  Ioannis G Koutlas; Bernd W Scheithauer; Andrew L Folpe
Journal:  Head Neck Pathol       Date:  2010-04-17

7.  Tight junction protein claudin-1 is differentially expressed in craniopharyngioma subtypes and indicates invasive tumor growth.

Authors:  Christina Stache; Annett Hölsken; Rudolf Fahlbusch; Jörg Flitsch; Sven-Martin Schlaffer; Michael Buchfelder; Rolf Buslei
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

Review 8.  Pathology and molecular genetics of meningioma: recent advances.

Authors:  Makoto Shibuya
Journal:  Neurol Med Chir (Tokyo)       Date:  2014-12-20       Impact factor: 1.742

9.  Expression of mesothelioma-related markers in meningiomas: an immunohistochemical study.

Authors:  Eman Abdelzaher; Dina Mohamed Abdallah
Journal:  Biomed Res Int       Date:  2014-04-30       Impact factor: 3.411

10.  Inversion-mediated gene fusions involving NAB2-STAT6 in an unusual malignant meningioma.

Authors:  F Gao; C Ling; L Shi; D Commins; G Zada; W J Mack; K Wang
Journal:  Br J Cancer       Date:  2013-07-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.